Search results for " KRAS"

showing 10 items of 26 documents

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

2010

An important molecular target for metastatic CRC treatment is the epidermal growth factor receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including EGFR activation markers and EGFR ligands activation markers. With regard to the "negative predictive factors" responsible for primary or intrinsic resistance to anti-EGFR antibodies a lot of data are now available. Among these, KRAS mutations have emerged as a major predictor of resistance to panitumumab or cetuximab in the clinical setting and several studies of patients receiving first and subsequent lines of treatment have sho…

OncologyColorectal cancerSettore MED/06 - Oncologia MedicaCetuximabDrug resistancemedicine.disease_causeEpidermal growth factor receptorEGFR; KRAS; Driver mutations; Monoclonal antibodiesCetuximabbiologyPanitumumabAntibodies MonoclonalGeneral MedicinePrognosisAntibodies Anti-IdiotypicErbB ReceptorsGene Expression Regulation NeoplasticOncologyMonoclonalKRASColorectal Neoplasmsmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtymedicine.drug_classEGFRMonoclonal antibodyAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Predictive Value of TestsInternal medicineProto-Oncogene ProteinsmedicineBiomarkers TumorKRASPanitumumabHumansRadiology Nuclear Medicine and imagingneoplasmsbusiness.industryPTEN PhosphohydrolaseMembrane ProteinsDriver mutationmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmMutationCancer researchbiology.proteinras ProteinsMonoclonal antibodiesbusiness
researchProduct

Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.

2010

<i>Objectives:</i> FOLFOX-4 and FOLFIRI are considered equivalent in terms of activity and efficacy as first-line chemotherapy in metastatic colorectal cancer (mCRC). The monoclonal antibody (mAb) cetuximab showed intrinsic activity as a single agent in mCRC and was approved in combination with CPT-11 for patients who failed previous CPT-11-based treatment. The purpose of this phase II study was to evaluate the activity and safety of FOLFOX-4 plus cetuximab in untreated mCRC patients. <i>Methods:</i> Untreated patients with measurable metastatic disease and expressing epidermal growth factor receptor (EGFR) received cetuximab at a loading dose of 400 mg/m<sup>2…

OncologyMaleCancer ResearchLung NeoplasmsOrganoplatinum CompoundsSettore MED/06 - Oncologia MedicaColorectal cancerMetastaseLeucovorinPhases of clinical researchCetuximabColorectal Neoplasmmedicine.disease_causeMetastasisFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene ProteinFOLFOX-4CetuximabLiver NeoplasmsAntibodies MonoclonalGeneral MedicineMiddle AgedErbB ReceptorsColorectal carcinomaOncologyLiver NeoplasmFOLFIRIFemaleKRASFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyAntibodies Monoclonal HumanizedBRAFProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsKRASmedicineHumansAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundCancerras Proteinmedicine.diseasedigestive system diseasesSurgeryLung NeoplasmMutationras ProteinsReceptor Epidermal Growth FactorbusinessBRAF; Cetuximab; Colorectal carcinoma; FOLFOX-4; KRAS; Metastases; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor Epidermal Growth Factor; ras Proteins; Oncology; Cancer ResearchOncology
researchProduct

The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevac…

2015

Bevacizumab-containing chemotherapy differently predict increased efficacy in KRAS exon 2 mutant and wild-type metastatic colorectal cancer (MCRC) patients. Mutant compared to wild-type status did not significantly affect progression-free survival (PFS) and overall survival (OS) in patients fit for first line bevacizumab-containing FIr-B/FOx regimen, and after progression. In patients unfit for intensive regimens, mutant status significantly affected PFS, while not OS. Codon 12 KRAS mutations differentially affect GTPase function, and confer worse clinical behaviour. Prognostic relevance of the prevalent c.35 G. >. A KRAS mutation was retrospectively evaluated. Fit c.35 G. >. A mutant patie…

OncologyVascular Endothelial Growth Factor APathologyKRAS c.35 G>A mutationColorectal cancermedicine.medical_treatmentMutantIntensive regimenColorectal Neoplasmmedicine.disease_causeExonMutation RateAntineoplastic Combined Chemotherapy ProtocolsNeoplasm MetastasisProto-Oncogene ProteinMetastatic colorectal cancerHematologyExonsPrognosisNeoplasm MetastasiBevacizumabTreatment OutcomeOncologyDisease ProgressionBiomarker (medicine)KRASColorectal NeoplasmsHumanmedicine.drugmedicine.medical_specialtyBevacizumabGenotypePrognosiExonAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsmedicineHumansChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryBiomarkerras Proteinmedicine.diseaseRegimenMutationras ProteinsBevacizumab; Biomarker; Intensive regimens; KRAS c.35 G>A mutation; Metastatic colorectal cancer; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Colorectal Neoplasms; Disease Progression; Genotype; Humans; Mutation Rate; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Vascular Endothelial Growth Factor A; ras Proteins; Exons; Mutation; Hematology; Oncology; Geriatrics and GerontologyGeriatrics and GerontologybusinessBiomarkers
researchProduct

1,2,4-Amino-triazine derivatives as pyruvate dehydrogenase kinase inhibitors: Synthesis and pharmacological evaluation

2023

: Among the different hallmarks of cancer, deregulation of cellular metabolism turned out to be an essential mechanism in promoting cancer resistance and progression. The pyruvate dehydrogenase kinases (PDKs) are well known as key regulators in cells metabolic process and their activity was found to be overexpressed in different metabolic alerted types of cancer, including the high aggressive pancreatic ductal adenocarcinoma (PDAC). To date few PDK inhibitors have been reported, and the different molecules developed are characterized by structural chemical diversity. In an attempt to find novel classes of potential PDK inhibitors, the molecular hybridization approach, which combine two or m…

PharmacologyPDK inhibitors4-Amino-triazines1Organic ChemistryDrug Discovery2124-Amino-triazinesGeneral MedicineKRAS-mutated pancreatic cancerLigand-based homology modelingSettore CHIM/08 - Chimica Farmaceutica124-Amino-triazines; KRAS-mutated pancreatic cancer; Ligand-based homology modeling; PDK inhibitorsEuropean Journal of Medicinal Chemistry
researchProduct

Zvaigžņotā Debess: 2009, Pavasaris (203)

2009

Contents: E.R.Mustel, President of the Astronomical Council of the USSR Academy of Sciences. Congratulations to Editorial Board of “Zvaigžņotā debess” ; Z.Alksne. Gould’s Belt ; I.Daube. At the Radioastrophysical Observatory of the Latvian Academy of Sciences ; Z.Alksne, A.Alksnis. Lopsided Galaxies ; A.Alksnis. HII Region Gum 29 – a Stellar Nursery ; D.Docenko. On Collision of Asteroid 2008 TC3 with the Earth ; V.Lapoška. On „Leap Second” ; I.Vilks, M.Gills. Beginning of the International Year of Astronomy in Paris: Impressions by Latvian Delegates ; J.Jaunbergs. Equatorial Ridge on Iapetus ; M.Sudārs. Space Shuttle Is Not Likely to Retire Next Year ; I.Vilks. Planet Satellite Names in Lat…

Planētu pavadoņu latviskie nosaukumiHII apgabals Gum 29Saules aptumsums - novērojumi - 2008. gada 1. augusts RīgaPublikācijas par astronomijuSaturna pavadonis Japets – kalnu joslaGalileja tālskatis – ESA/NASA Habla Kosmiskais teleskopsAstronomija skolāZiemeļvalstu optiskais teleskops (Nordic Optical Telescope) Kanāriju salāsApsveikums „Zvaigžņotās debess” redakcijai„Liekā” sekundeDr.habil.phys. Juris Tambergs (1942-2008)Latvijas PSR ZA Radioastrofizikas observatorija – vēstureAicinājums astronomijas atbalstītājamRīgas Politehnikuma observatorijas tornis – vēstureStarptautiskais Astronomijas gads 2009Fizikas autodidakts Roberts KrastiņšSpirāliskās galaktikas – asimetrijaNovērojumi Rīgas Politehnikuma tornī - pirmā publikācijaĒrgļa Sigma seminārs – daļējs Mēness aptumsumsVisuma tēma filatēlijā – kosmiskās ēras sākumsSaules aptumsums - novērojumi - 2008.gada jūlijs SibīrijaPublisko demonstrējumu observatorija RāmkalnosDr.habil.math. Aivars Lorencs - intervijaAstronomiskās parādības - 2009Asteroīda 2008 TC3 sadursme ar ZemiNASA Space Shuttle programmas pagarinājumsLatvijas jauno matemātiķu izlase - 2008.gads“Noteikumi par līgumu starp Latvijas Republikas valdību un Eiropas Kosmosa aģentūru par sadarbību kosmosa jomā miermīlīgiem mērķiem” - projektsLU profesors Edgars Lejnieks (1919-1934)Jānis Klētnieks „Mūžības valdnieki”Ūdens marsiešiemLatvijas atklātā skolēnu astronomijas olimpiāde
researchProduct

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Proto-Oncogene Proteins B-rafCancer ResearchPrognosiColorectal cancerCetuximabColorectal Neoplasmmedicine.disease_causeBRAFProto-Oncogene Proteins p21(ras)FOLFOXProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsKRASmedicineHumansPanitumumabEpidermal growth factor receptorBRAF; Cetuximab; Colorectal carcinoma; KRAS; Panitumumab; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Receptor Epidermal Growth Factor; Signal Transduction; ras Proteins; Cancer Research; OncologyneoplasmsProto-Oncogene ProteinClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCetuximabbiologybusiness.industryPanitumumabGeneral Medicineras ProteinPrognosismedicine.diseasedigestive system diseasesOxaliplatinErbB ReceptorsColorectal carcinomaOncologyMutationras ProteinsCancer researchFOLFIRIbiology.proteinReceptor Epidermal Growth FactorKRASPredictive factorColorectal NeoplasmsbusinessHumanSignal Transductionmedicine.drugOncology
researchProduct

Latvijas arheologu atskaites sesija par 2016.-2017.gada izrakumu rezultātiem: referātu tēzes

2018

Riņņukalna neolīta apmetne - izrakumiRīgas iela Cēsīs - arheoloģiskā izpēteLudzas viduslaiku pils - izpēteGrobiņas pilskalns un senpilsēta - arheoloģiskā izpēte:HUMANITIES and RELIGION::History and philosophy subjects::Archaeology subjects [Research Subject Categories]Ķīšukalns - izrakumiArheoloģiekie izrakumi - LatvijaAntropoloģiskā materiāla paleopataloģiskā izpēteArheoloģiskā izpēte - LatvijaDobeles Livonijas ordeņa pilsdrupasDarvas tecinātava Dundagas pagastā pie Ventnieku mājām - izpēteAlūksnes Tempļa kalns - izrakumiKvartāls Rīgā starp Mārstaļu ielu 11. novembra krastmalu un Minsterejas ielu - arheoloģiskā izpēte
researchProduct

Admissible perturbations of alpha-psi-pseudocontractive operators: convergence theorems

2015

In the last decades, the study of convergence of fixed point iterative methods has received an increasing attention, due to their performance as tools for solving numerical problems. As a consequence of this fact, one can access to a wide literature on iterative schemes involving different types of operators; see [2, 4, 5]. We point out that fixed point iterative approximation methods have been largely applied in dealing with stability and convergence problems; see [1, 6]. In particular, we refer to various control and optimization questions arising in pure and applied sciences involving dynamical systems, where the problem in study can be easily arranged as a fixed point problem. Then, we …

Settore MAT/08 - Analisi NumericaSettore MAT/05 - Analisi Matematicaalpha-admissible mapping alpha-psi-pseudocontractive operator Hilbert space Krasnoselskij type iterative scheme.
researchProduct

Application of the LISS Lyapunov-Krasovskii small-gain theorem to autonomously controlled production networks with time-delays

2010

Accepted version of a paper published by IEEE. (c) 2010 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other users, including reprinting/ republishing this material for advertising or promotional purposes, creating new collective works for resale or redistribution to servers or lists, or reuse of any copyrighted components of this work in other works Published version: http://dx.doi.org/10.1109/SYSTOL.2010.5676085 In this paper we consider general autonomously controlled production networks. A production network consists of geographically distributed plants, which are connected by transport routes such that transportation times (time-delays) …

VDP::Mathematics and natural science: 400::Mathematics: 410::Applied mathematics: 413Time delaysSmall-gain theoremDifferential equationProperty (programming)Control theoryProduction controlVDP::Technology: 500::Mechanical engineering: 570Lyapunov krasovskiiProduction (economics)Stability (probability)Mathematics2010 Conference on Control and Fault-Tolerant Systems (SysTol)
researchProduct

Kultūrvēsturisko pilsētbūvniecības ansambļu saglabāšana: Slokas centra piemērs

2018

Sloka pēdējās desmitgadēs ir piedzīvojusi nopietnas sociālas izmaiņas ar ietekmi uz tās pilsētvidi. Mūsdienu situācija, atrodoties Jūrmalas pilsētas nomalē, ne vienmēr ir labvēlīga, lai tajā arī turpmāk varētu būt nozīmīgi pakalpojumu centri un pastāvīgajiem iedzīvotājiem paredzēts dzīvojamais fonds, dzīvojamā apkaime. Vietizpētei izvēlētais Slokas centrs piesaista ar tajā vēl joprojām esošajām un saskatāmajām pilsētvides vērtībām: cilvēku vajadzībām un ģeogrāfiskajam novietojumam atbilstošu un plānotu vidi, publiski pieejamu Lielupes krastmalu. Darbā sniegta šī brīža situācijas dokumentācija un analīze, veidots salīdzinājums ar līdzīgiem apdzīvotu vietu piemēriem, lai parādītu, ka arī šāda…

iekšpilsētaauthentic placeArhitektūrainner citydzīvotspējīga pilsēta postindustriāla pilsēta ģentrifikācija pilsētvides mantojums ilgtspējīga apkaime krastmalaautentiska vieta
researchProduct